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Molecul ar Method
Blood centers are in the unique position to evaluate large 
numbers of blood donations for antigen-negative blood types. 
The limitations with the use of hemagglutination, however, can 
be circumvented with red cell genotyping. The reagents used for 
genotyping are synthesized and can be designed for any of the 
known blood group antigen single nucleotide polymorphisms 
that are associated with blood group antigen expression. There 
is interest in the application of mass-scale red cell genotyping of 
blood donors to find rare phenotypes and rare combinations of 
antigens. When performed on donors who are predicted to donate 
again after testing, integrating the genotype information with 
existing donor data and demographics provides the blood center 
with real-time information to identify the common clinically 
relevant blood group antigens demanded by hospital transfusion 
services. This review outlines a red cell genotype methodology 
using TaqMan chemistry and existing algorithms and data 
handling to gain the full value of mass-scale red cell genotyping 
of blood donors. Immunohematology 2015;31:69–74.
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Transfusion recipients who become alloimmunized to 
blood group antigens require crossmatch-compatible blood 
that is negative for the cognate antigens. Blood collection 
facilities have the responsibility of finding antigen-negative 
blood among donor units. Historically, manual and automated 
phenotyping methods are still used to screen blood donations 
routinely for antigen-negative types that are likely to be in 
demand.1 The screening is done with a limited collection 
of licensed or unlicensed blood grouping reagents, and the 
results are recorded for later use should a blood donor donate 
again. Knowing the donor’s history of donations provides 
efficiencies to antigen typing programs because repeat donors 
are predicted to donate in the future and do not need to be 
repeatedly typed.
Knowledge of the molecular basis of blood group 
expression2 and the development of platforms capable of 
screening on a mass scale3 have created the opportunity to 
screen blood donors for antigen-negative types using DNA 
rather than red blood cells. High-throughput genotyping 
platforms can enable mass-scale screening when the output 
files from these instruments are electronically interfaced with 
the laboratory information management system (LIMS), 
making red cell genotyping an attractive screening alternative 
to hemagglutination-based platforms. A desired goal for a 
blood center is to have enough antigen-negative blood units 
to meet approximately 95 percent of blood requests that 
it receives.4 For blood centers that support the American 
Rare Donor Program, comprehensive genotyping of a large 
number of donors contributes to the desperately needed 
rare blood types at an incremental cost to screening for the 
common blood group antigens of the RH, MNS, Kell, Duffy, 
and Kidd systems. This article outlines a method used to 
genotype blood donors on a high-throughput mass scale using 
TaqMan chemistry. Several manufacturers have instruments 
that use TaqMan chemistry and can be designed for red cell 
genotyping. Systems that have been evaluated for red cell 
genotyping using TaqMan technology include the Wafergen 
SmartChip (Wafergen Biosystems, Fremont, CA), Fluidigm 
June 96.96 Genotyping IFC (Fluidigm, South San Francisco, 
CA), and QuantStudio 12K Flex Real-Time PCR System (Life 
Technologies, Grand Island, NY).
Red Cell Genotyping
Red cell genotyping platforms are based on the polymerase 
chain reaction (PCR) coupled with nucleic acid chemistry that 
can be performed with rapid turnaround time. A desirable 
turnaround time from setup to result output is in the 6- to 
8-hour range. When used to screen a large number of donor 
samples for antigen-negative blood types (i.e., mass-scale), 
data parsing and comparative analysis of the results with other 
donor information optimally should follow within 24 hours. At 
a maximum, the process should be completed to coincide with 
the release of blood units after infectious disease testing.
The term “array” used in this review refers to platforms 
that simultaneously interrogate a multitude of single nucleotide 
polymorphisms (SNPs) in a single format, whether or not the 
array is attached to a support like a bead or chip. An “open” 
system refers to the fact that the make-up of the array can be 
changed with minimal to no impact on platform performance. 
This flexibility is based on the fact that the assays are not 
multiplex; each assay is a single reaction performed in a single 
well. The design layout can therefore be altered at the discretion 
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of the operator, simply by expanding the number of assays or 
excluding one assay and introducing another.
The term “high-throughput” applies to any platform 
regardless of the nucleic acid chemistry: PCR–enzyme-
linked immunosorbent assay (ELISA), PCR–oligonucleotide 
extension, sequence-specific PCR–mass spectrometry, and 
PCR–oligonucleotide hybridization all have high-throughput 
capability. For red cell genotyping of donors, this term means 
that blood units are tested and the desired antigen-negative 
units are identified before the blood unit leaves the control of 
the blood center. Mass-scale genotyping is achieved when an 
array of SNPs is analyzed on many samples. The method for 
high-throughput mass-scale red cell genotyping includes DNA 
extraction, genotyping, and data transfer to a LIMS. Process 
control is achieved by collecting metrics at key steps that will 
identify process failures should they occur. Desirable metrics 
are:
• DNA concentration and the OD260/280 ratio
– A concentration or ratio less than a given threshold = 
sample extraction failure
• Evaluation of the result values (fluorescence integrity)
– Lack of passive dye (e.g., ROX™ Passive Reference 
Dye) detected during results imaging = DNA load 
failure
• Genotype results of known controls
– Controls that fail to give the expected result = an assay 
or run failure
• Genotype results of unknown samples
– Outlier, Do not Call, or No Call flags across multiple 
assays = sample failure (likely because of a DNA 
extraction or load failure)
– Unexpected combinations of SNPs (e.g., homozygous 
FY GATA mutation with FY*A/FY*B)
OpenArray Genotyping System Workflow
The OpenArray Real-Time PCR System (Life 
Technologies) is summarized here. It uses real-time PCR–
fluorogenic 5´ nuclease TaqMan chemistry and is available 
as the QuantStudio 12K Flex system. TaqMan chemistry can 
discriminate between SNPs by using specifically designed 
pairs of single-stranded DNA oligonucleotide probes and the 
5´ to 3´ exonuclease activity of Taq polymerase.5 Each TaqMan 
probe consists of a short single-stranded oligonucleotide 
containing a 5´ fluorophore (e.g., 6-carboxyfluorescein 
[FAM] or 4,7,2 -́trichloro-7 -́phenyl-6-carboxyfluorescein 
[VIC]) and a 3´ quencher (e.g., tetramethylrhodamine 
[TAMRA]). The principle was named TaqMan in reference 
to its similarity with the PacMan video game: the 5´ to 3´ 
exonuclease activity of Taq polymerase degrades a hybridized 
probe during PCR amplification. In brief, a TaqMan assay 
comprises two amplification primers and two probes of 
approximately 20 nucleotides that differ by one SNP. The Taq 
polymerase extends the amplification primers in the 3´ to 
5´ direction during the elongation stage of PCR. The single-
stranded DNA oligonucleotide probes anneal to the region 
containing the SNP of interest. With each successive round, 
as the polymerization encounters a hybridized probe, the 5´ 
to 3´ exonuclease activity degrades the probe and releases the 
fluorophore from the quencher. The observed fluorescence is 
an indication that a particular probe was annealed and the 
SNP is present (Fig. 1). The SNP discrimination is attributable 
to the poor hybridization that each probe has for the alternate 
allele containing the mismatched nucleotide. Mismatched 
probes are not hybridized efficiently and are not degraded. 
Because SNPs represent the molecular basis of many blood 
group antigens, a pair of TaqMan probes can determine the 
three possible genotypes. TaqMan technology can also be used 
to distinguish nucleotide insertions (or deletions) because one 
probe can be specific to the insertion sequence and the other 
probe can be designed to anneal across the deletion (e.g., the 
17–base pair deletion of the common Vel– genotype6).
Materials and Methods
The red cell genotyping method described in the proof-
of-principle7 consists of three major steps: DNA extraction 
templated on a 96-well format; red cell genotyping (assay 
Fig. 1. The principle of the TaqMan assay involves prevention of 
fluorescence of a fluorophore by the close proximity with a quencher 
in a nucleotide probe. As the Taq polymerase reaches the probe, the 
5´ to 3´ exonuclease activity of the polymerase degrades the probe, 
the fluorophore is released from the quencher, and fluorescence 
is detected (left panels). A typical TaqMan assay has two such 
probes that detect a single nucleotide difference at a specific 
location between two alleles of a given gene. Probes that are not 
100 percent homologous with the DNA sequenced do not bind 
sufficiently and the Taq polymerase cannot degrade the probe to 
release the fluorophore from the quencher (right panels).
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setup, PCR amplification, and fluorescence measurement), 
and results analysis. Electronic uploading to a LIMS is 
included in the methodology because it is desirable to compare 
existing historical phenotype with genotype results, including 
D antigen. Without this electronic data step, high-throughput 
genotyping is reduced to mass-scale testing followed by 
perusal of instrument printouts for desired antigen-negative 
genotypes.
The OpenArray system requires the use of a robotic 
sample loader for the arrays (OpenArray Accufill System, Life 
Technologies) because an array consists of 3072 open wells. 
The OpenArray is a thin stainless steel wafer comprising holes 
capable of holding 33 nL of fluid that are precision-drilled in 
an arrangement of 48 matrices or subarrays. Each subarray 
is configured in an 8 × 8 format. The hydrophobic exterior 
of the wafer maintains the liquid inside the wells. Each well 
is preloaded with a TaqMan assay by the manufacturer. 
Genomic DNA concentrations can range from 10 to 50 ng/µL, 
with the higher concentration preferred because the nano-
volume reduces the input DNA to approximately 80 genome 
equivalent, or 40 copies of an allele for a heterozygous 
sample. For red cell genotyping, 32 TaqMan assays custom-
designed to identify 42 common and rare blood group 
antigens are preloaded into the wells.3 Therefore, each 
8 × 8 subarray consists of two sets of four rows containing 
the 32 assays (Fig. 2). The instrument can handle up to four 
arrays in a single run. The attractive feature of single-well 
testing is the flexibility to change one or more assays without 
compromising the validity of other assays, since each well 
represents a single TaqMan reaction. Arrays must be ordered 
as a minimum of a set of 10, however.
DNA Extraction
Any DNA extraction method is acceptable provided the 
yield is greater than 10 ng/µL and of high purity (OD260/280 
nm ratio: 1.7 ± 0.2). ISBT unit barcodes can be used as the 
sample ID electronically scanned into a 96-well template, 
which matches the number of samples interrogated in a 
single array. A PCR-grade water “sample” serves to evaluate 
cross-contamination during DNA extraction and can be used 
as the No Template Control (NTC) during genotyping. The 
DNA concentration and OD206/280 nm ratio is measured on 
a subset of samples from each 96-well plate using an eight-
channel spectrophotometer by Nanodrop chemistry. If one of 
the eight samples falls outside the acceptable limits, the entire 
plate can be evaluated for repeat extraction. Alternatively, all 
samples can be evaluated and then the decision made whether 
individual samples should be subjected to DNA extraction or 
whether the extraction run failed. The extraction of DNA into 
removable eight-well strips facilitates the replacement of any 
one column with a set of DNA controls that are pre-pipetted 
into eight-well strips.
Red Cell Genotyping Steps
1) Array setup for 384 samples: Typically, a set of 16 controls 
and 4 NTCs are included with each batch of 4 arrays. In 
this way, 364 unknown samples can be interrogated in a 
single run. A batch of 4 arrays potentially produces 15,288 
discrete results (91 unknown samples per array × 4 arrays 
× 42 blood group antigens). The initial sample and master 
mix setup has three steps that can be performed with an 
8- or 12-multichannel micropipettor.
a. Pipette the master mix (Taq polymerase, dNTPs, and 
PCR buffer) into a 384-well plate
b. Pipette DNA samples, controls, or NTCs into the 384-
well plate
c. Use the robotic OpenArray AccuFiller to distribute the 
samples from the master plate to the subarrays
2) PCR amplification: The arrays are placed into cassettes 
and sealed with an oil-based product. The arrays are laid 
flat on a standard thermal cycler that has been fitted with 
an array holder. The assays are designed for standard 
TaqMan two-stage cycling as outlined in Table 1.
3) Fluorescence measurement: After PCR amplification, the 
arrays are evaluated for FAM and VIC fluorescence. The 
array can be evaluated for fluorescence integrity if the 
Fig. 2. A schematic diagram of an OpenArray (Life Technologies). 
Each wafer consists of 48 subarrays (bottom) arranged in matrices 
of 8 × 8 wells (magnified on the right) and capable of holding 33 nL 
of fluid. The negative hydrophobic nature of the outside maintains the 
fluid within the hydrophilic wells (© 2015 Thermo Fisher Scientific 
Inc. Used under permission).
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master mix contains a passive fluorescence dye like ROX. 
The passive dye fluorescence evaluation allows each well 
to be assessed for DNA content.
4) Results analysis: The platform software assigns samples 
with similar FAM/VIC fluorescence ratios into single 
groups, which represents the three genotype clusters. Any 
result that does not meet the stringency set by the software 
is defined as “Outlier” (excessively high fluorescence), a 
“Do Not Call” (no cluster designation), or a “No Call” (low 
fluorescence), each of which are excluded from assigning a 
result to the output file. Essentially, a sufficient number of 
DNA controls are tested such that the software correctly 
assigns the value to the expected homozygous genotypes 
and the heterozygous genotype. Assays that interrogate 
SNPs for rare blood group genotypes such as Yt(a–) may 
not have sufficient data for the software to assign a cluster. 
In these instances, the rare homozygous cluster can be 
defined by the operator or assumed on the basis of the 
two remaining genotype clusters. Controls that do not 
generate a result or are not assigned to the correct cluster 
indicate that the assay has failed. Unknown samples that 
reproducibly lie outside a cluster for a particular assay 
may be an indication of a possible variant allele and can 
be further evaluated by manual molecular methods.
Upload to a LIMS
The advantage of red cell genotyping is the ability to 
manufacture synthetic reagents for assays that interrogate 
the vast number of SNPs associated with blood group antigen 
expression. Thus, the output of high-throughput mass-scale 
testing creates “big data” that cannot be reasonably scanned 
by eye or reviewed on a sample-by-sample results basis. 
End-to-end connectivity from DNA extraction to predicted 
phenotype display is necessary and can be accomplished 
by parsing the instrument output file, composed of the A, 
C, G, or T nucleotides, and then translating the parsed data 
into predicted phenotypes using a defined electronic rules 
engine.8 We chose to express predicted phenotypes using ISBT 
nomenclature (e.g., FY1) to distinguish them from serological 
phenotypes (e.g., Fya). The predicted phenotype data set is 
then aligned with other phenotype and donation information. 
Figure 3 summarizes the steps necessary to upload the data 
to be compatible with a blood center LIMS. The parsed data 
and donor information can be subjected to logical arguments 
to create exception reports. The following exception reports 
provide important control and information throughout the 
entire red cell genotyping process:
• Donor did not meet repeat donation criteria
• Previous genotype does not match current genotype 
(repeat testing control)
• Donor genotyped twice (selection criteria not met)
• Phenotype does not match genotype (discrepancy)
• RHD detected in a D– donor (serologic weak, Del, or 
non-functional allele)




TaqMan open array systems are very flexible. QuantStudio 
arrays can be formatted to run 16 assays on 144 samples, 32 
assays on 96 samples, or 64 assays on 48 samples. Array 
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Table 1. Thermal cycling conditions for real-time array polymerase 
chain reaction
Temperature (°C) Time (min) Cycles Ramp rate (%)
93 10:00 1 100
95 00:45 84
94 00:13 40–50 100
53 2:14 44
25 2:00 1 100
4 Hold
Fig. 3. Summary of the steps taken to import, translate, parse, and 
analyze red cell genotyping data in relation to donor information. 
Queries and reports can be designed to extract useful predicted 
phenotype (genotype) information. Predicted phenotypes are 
distinguished from antigen phenotypes by using a distinct 
nomenclature (not shown).
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setup, PCR amplification, fluorescence evaluation, and results 
analysis for a run of four arrays in a single run of 32 assays 
on 96 samples plus controls (n = 384) consumes about 2.5 
hours of hands-on time and can be accomplished comfortably 
in a single 8-hour shift. The equivalent hands-on time using 
a manual TaqMan and 96-well microplate format run on a 
fluorescent-based instrument (e.g., Lightcycler) would be three 
samples plus controls. The QuantStudio Accufiller provides 
the automation necessary for the critical sample loading 
step. Reagent costs include DNA extraction, TaqMan assays, 
master mix, nanofluidic arrays, and precision pipette tips for 
nanoliter dispensing. Fixed costs including capital equipment 
(depreciated over 7 years), reagents and consumable costs, 
along with hands-on time and data review places the overall 
cost at approximately $1.35 per SNP.
One advantage of an “open” system is the ease of assay 
design and validation. Each assay is designed and tested 
for robustness in separate validation experiments. The 
probe length and position across the SNP of interest can be 
adjusted so that the assay performs optimally using one 
TaqMan amplification profile. Software programs exist that 
help with the in silico design of amplification primers and 
TaqMan probes; typically, adjustments to optimize an assay 
are needed in about 10 percent of all assays developed. Once 
validated using the standard protocol, the assay can be added 
to the platform. For example, the gene responsible for the 
expression of Vel was reported in 2013, and a TaqMan assay 
was developed shortly thereafter. It could not be added to a 
multiplex assay without re-validating all the remaining assays 
in the mix. Nevertheless, using a single reaction well design, 
the Vel assay was validated and could be added to the suite, 
or substituted for another to maintain a preset format of, for 
example, 32 assays. In addition, as phenotype–genotype 
discrepancies identify low-frequency nucleotide variation that 
affects performance, assays can be redesigned to account for 
this variant nucleotide. This feature is particularly attractive 
when a founder allele is identified among an ethnic or racial 
population.
As with any nucleic chemistry, the TaqMan principle has 
some weaknesses. Genotyping methods that rely on PCR to 
amplify a region of interest before interrogation are error-
prone to nucleotide variation in the region of the amplification 
primers. Nucleotide variations in these regions can appear as 
functional hemizygotes. In other words, only the single non-
variant allele is amplified, and the sample appears homozygous 
for the associated SNP. A low-frequency nucleotide variation 
in the region of the oligonucleotide probes affects TaqMan 
assays. A probe will not have sufficient homology to an SNP 
if there is a mismatch elsewhere in the probe. The sample 
will appear homozygous for the alternate SNP that does not 
contain the variant nucleotide. For regions with known SNPs 
in close proximity, Taqman assays can be designed with 
inosine incorporated into the probes to compensate for the 
destabilizing effect of a nearby SNP.9
Validation of Custom Assays
We prefer to evaluate 10 samples of each genotype (10 
homozygous, 10 heterozygous, 10 low frequency) for SNPs that 
have relatively equal allele frequencies. For rare blood group 
antigens, we test 10 of the common antigens, and as many 
heterozygous samples as can be reasonably found, and one 
rare homozygous allele. Without at least one rare homozygous 
allele, the three genotype clusters cannot be defined and with 
that shortcoming, the heterozygous cluster may not be clearly 
defined.
Implementation
Mass-scale testing can be implemented for one of two 
purposes. Red cell genotyping can be intended to be used 
as a screening tool, with the results confirmed by serology 
with licensed or unlicensed antisera, or alternatively can be 
confirmed by a validated molecular test. As of April 2014, 
Immucor’s PreciseType is the only U.S. Food and Drug 
Administration–licensed molecular test for RBC genotyping. 
Lab developed tests that have been validated in compliance 
with national lab standards present an alternative at the 
present time.
When used as a screening tool, assay robustness may be 
relaxed so that the number of samples tested is maximized. 
This approach means that assays with high guanine/cytosine 
content or that show a limited variation are still acceptable 
for use because (1) clustering will for the most part exclude 
these samples from assigning a wrong genotype and (2) the 
confirmation of antigen expression performed to label blood 
units will identify discrepancies. When implemented as a 
screening tool, our preference is to optimize assays such that 
the number of samples that are not assigned a genotype (the 
No Call rate) is less than 1 percent for 90 percent of the assays, 
with no assays having a No Call rate exceeding 5 percent.3 
Otherwise, too much data are irretrievably lost.
We have evaluated over 50,000 samples using TaqMan 
assays in an open platform design. Whether the approach 
will be widely adopted in transfusion medicine is uncertain. 
The flexible design and development costs per assay, along 
with multiple platform choices, make it attractive to become 
the preferred screening tool for rare antigens among donors. 
Mass-scale red cell genotyping
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The flexibility does have the disadvantage that reagent 
quality control is the responsibility of the purchaser of the 
platform. The lack of commercially available reagent kits relies 
on collaborative agreements between institutions to share 
technical information. Otherwise, the utility of this approach 
is limited to labs with the technical expertise to design their 
own assays and the availability of rare DNA genotyped 
samples from repositories such as the Serum Cells and Rare 
Fluids exchange.
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